Computation modelling method to estimate secondhand exposure potential from exhalations during e-vapor use under various real-world scenarios

Jeffery S. Edmiston  
Altria Client Services Inc

Ali Rostami  
Altria Client Services Inc

Qiwei Liang  
Altria Client Services Inc

Sandra Miller  
Altria Client Services Inc

Mohamadi Sarkar (✉ mohamadi.sarkar@altria.com)  
Altria Client Services Inc  https://orcid.org/0000-0002-1167-6140

Research

Keywords: conventional cigarettes, electronic cigarettes, electronic vapor products, exhaled breath, non-user exposure, passive vaping, secondhand smoke

DOI: https://doi.org/10.21203/rs.3.rs-341609/v1

License: ☺️  This work is licensed under a Creative Commons Attribution 4.0 International License. 
Read Full License
Abstract

Background: The potential secondhand exposure of exhaled constituents from e-vapor use, particularly under various real-world setting, is a public health concern. We present a computational modelling method to predict air levels of constituents exhaled from e-vapor product use.

Methods: We first conducted a clinical study to measure select constituent levels in exhaled breath from adult e-vapor product users. We then used a computational model to predict levels of these constituents in three scenarios – in a car, office and restaurant to determine likely secondhand exposure to nonusers. Exhaled breath samples (10 controlled puffs) were analyzed after the use of four different e-liquids in a cartridge-based e-vapor product. Seven selected analytes were measured: nicotine, propylene glycol (PG), glycerin, menthol, formaldehyde, acetaldehyde, and acrolein and reported based on a linear mixed model for analysis of covariance.

Results: The ranges of nicotine, propylene glycol, glycerin, and formaldehyde in exhaled breath were 89.44-195.70 µg, 1,199.7-3,354.5 µg, 5,366.8-6,484.7 µg, and 0.25-0.34 µg, respectively. Menthol was only detected following mentholated e-vapor product use (21.11-31.01 µg); acetaldehyde and acrolein were below detectable limits.

Conclusions: We utilized a previously validated well-mixed model to estimate aerosol dispersion and room air levels of individual constituents. The model was based on physical and thermodynamic interactions between air, vapor, and the particulate phase of the aerosol to predict vapor-particle partitioning and air-levels of constituents over time, as they travel through a defined indoor space. Input variables included space setting (space type and volume such as car, office space, or a restaurant), ventilation rate, the amount of total aerosol exhaled by all users and aerosol composition. The computational model predicted that air levels of nicotine, formaldehyde, acrolein, and acetaldehyde were below the permissible exposure limits set by authoritative bodies and substantially lower during e-vapor use compared to conventional cigarettes. The relatively low levels suggest minimal exposure to nonusers.

Trial registration: Awaiting Clintrials Registry Number. In the process of retrospectively registering the study in the US Clinicaltrials Registry (http://www.clintrials.gov) will update the information as soon as registered.

Introduction

Electronic vapor products (EVPs) are a growing segment of the tobacco category. These devices may offer adult tobacco consumers a reduced risk product compared to conventional, lit-end cigarettes and play an important part in tobacco harm reduction [1–3]. EVPs deliver nicotine in an aerosol that has a very different composition from conventional cigarette smoke [4–6]. Many of the chemicals generated from the combustion of tobacco are harmful [7, 8]. In contrast, heating an e-liquid consisting of carrier constituents (e.g., propylene glycol or glycerin), nicotine, water, and flavors generates far fewer harmful chemicals in much lower levels than the burning of tobacco [4, 9]. However, EVP aerosols may contain
some chemicals like carbonyls, volatile organic constituents, and metals [5, 10]. The inhaled EVP constituents are delivered to the user’s mouth, throat, and lungs during use and may be released into the environment during exhalation. Understanding the potential exposure of EVP exhaled constituents to non-users of EVPs is an important part of assessing their overall potential for harm reduction. However, few studies have assessed the levels of constituents contained in the exhaled breath of EVP users and air levels under various real-world scenarios to estimate potential exposure to non-users [5, 11, 12].

Results from quantitative and qualitative studies show a wide range of analytes in the aerosols of EVPs [13, 14]. Most studies use smoking machines to generate and directly collect the EVP aerosol [15] Data from such studies do not consider the uptake of the aerosol by the user. While sidestream smoke from a smoldering cigarette and smoker exhalations are both non-user exposure sources from a conventional cigarette, the aerosol exhaled into the environment by the user is the only potential source for secondhand exposure during EVP use [16]. Accurate estimates of the level of constituents within aerosols exhaled after EVP use can be used to model potential exposure to non-users under a variety of space and use conditions.

The purpose of this study was to characterize the level of selected aerosol constituents in exhaled breath after use of four different e-liquids in a cartridge-based EVP. In addition, we used the exhaled breath concentrations to model the constituent levels in the air of several indoor space configurations and usage scenarios to understand the potential for secondhand exposure to non-users. As the EVP segment of the tobacco category continues to grow, the models used in this research can provide insight into how non-users may be exposed to EVP constituents in different space and real-world use scenarios.

**Methods**

**Exhaled breath collection study design**

This study was an open-label, four-way crossover study designed to measure nicotine, propylene glycol, glycerin, menthol, formaldehyde, acetaldehyde, and acrolein levels in exhaled breath samples during the use of four e-liquids in an unbranded EVP. We selected these constituents because nicotine, propylene glycol, glycerin, and menthol are major ingredients in the e-liquid and formaldehyde, acetaldehyde, and acrolein are considered harmful and potentially harmful constituents. The in-clinic study was a single-center trial conducted in North Carolina. All EVP use and assessments occurred on-site. Compliance was monitored and recorded by site personnel and representatives from the contract research organization monitoring the study (Cato Research, Durham, NC). The study was conducted in accordance with Good Clinical Practice (GCP) based on the International Conference on Harmonization guidelines for GCP, and the corresponding sections of the United States Code of Federal Regulations (CFR) governing the Protection of Human Subjects (21 CFR 50), Institutional Review Boards (IRBs; 21 CFR 56), and the Basic Principles of the Declaration of Helsinki. Prior to the start of the study, the protocol and informed consent form were approved by an independent IRB.
Subjects were randomly assigned by sex to one of four use sequences in a 1:1:1:1 ratio (n = 8 subjects in each sequence: ABDC, BCAD, CDBA, or DACB). Subjects used one e-liquid per day in the order of their assigned sequence.

On each study day, subjects completed a morning exhaled-breath session with their assigned e-liquid. After session completion, subjects were allowed ad libitum use of their assigned e-liquid with new cartridges and freshly charged batteries for the next 12 hours with puff topography assessment (data not shown). Subjects underwent end-of-study assessments and were released from the site upon completion of the ad libitum-use session on Day Four.

**Participant selection**

Subject candidates were required to provide voluntary consent to participate and meet certain criteria before study enrollment: adults (21 to 65 years of age, inclusive), generally healthy, users of nicotine-containing EVPs for at least 3 months, users of nicotine-containing EVPs (some days or every day) for the past 30 days and at least 4 out of the past 7 days, and a positive urine test for tobacco use. All subjects had to be willing to use the EVPs after a brief test trial on Day One that consisted of ad libitum use for 10 minutes with each test e-liquid separated by ~30 minutes from the end of one trial to the start of another. Subjects who agreed to comply with the study procedures and met all other inclusion criteria and no exclusion criteria were eligible to participate. Eligible subjects checked in to the clinic the day before the exhaled breath collections started and were confined to the clinic for the remainder of the study.

**EVPs**

- The EVPs were unbranded versions of MarkTen® XL (Nu Mark LLC, Richmond, VA). The Test products that are no longer sold commercially and discontinued since December 2018. Each consisted of a standard battery and cartridge while sham EVPs had inactivated batteries and empty cartridges. Subjects used the assigned e-liquid on each study day:
  
  - Test Product 1: MarkTen® Fusion (2.5% nicotine by weight, NBW);
  - Test Product 2: MarkTen® Bold Classic (4.0% NBW);
  - Test Product 3: MarkTen® Winter Mint (3.5% NBW); and
  - Test Product 4: MarkTen® Bold Menthol (4.0% NBW).

  The solution weight in an unused cartridge was ~900 mg for all four e-liquids.

The seven analytes were measured for each e-liquid using a puffing machine with 20 puffs per cartridge using a 5-second puff duration and 55-cc puff volume at 30-second inter-puff intervals (Supplemental Table S1).17

**Exhaled breath sample collection and analyses**

Each exhaled-breath session consisted of: (1) sample collection during use of an EVP with an empty cartridge and an inactive battery (sham condition), (2) sample collection using the assigned e-liquid with
all exhaled breath collected in Trapping Container One (which captured nicotine, propylene glycol, glycerin, and menthol) for both sham and EVP collections, (3) at least 45 minutes of rest, (4) repeated sham sample collection, and (5) sample collection with Trapping Container Two (which captured formaldehyde, acetaldehyde, and acrolein) for both the second sham and EVP collections. Both types of trapping containers were supplied by Enthalpy Analytical, Inc. (Durham, NC). Each sample consisted of all the exhaled breaths occurring during 10 puffs, each with 5-second puff duration (± 1 second), for approximately 5 minutes (1 puff approximately every 30 seconds) collected in the respective sample collection containers. These collections took place in the morning during Days One through Four of in-clinic confinement.

**Exhaled breath trapping containers**

The exhaled breath condensate samples were collected using a fresh Single-Subject Sampling Kit provided by Enthalpy Analytical (Richmond, VA). Two trapping container systems were used with different filter configurations depending on the analytes of interest. The particulate filter for Trapping Container One consisted of a single 50mm AirLife Bacterial/Viral filter housed in a plastic filter holder. The filter was removed from the holder and used for measurement of nicotine, propylene glycol, glycerin, and menthol. The same measurements were performed for liquid in the cryogenically cooled trap after it was removed from the exhaled breath sample collection system. The filter system for Trapping Container Two consisted of two 50-mm AirLife Bacterial/Viral filters housed in a plastic filter holder. The liquid in the cryogenically cooled trap was removed from the exhaled breath sample collection system, treated on-site with 2,4-dinitrophenylhydrazine, and analyzed for formaldehyde, acetaldehyde, and acrolein. Upon completion of sample collection, the exhaled breath sample-collection systems were transported to Enthalpy Analytical for high-performance liquid and gas chromatography analyses as described in detail elsewhere [17].

**Statistical analyses**

A linear mixed model for analysis of covariance (ANCOVA) was used on the sham-adjusted analyte levels in the exhaled breath samples. The model included sequence, EVP, and period as fixed effects; sham sample value as a fixed covariance; and subject nested within-sequence as a random effect. All values of analytes in the exhaled samples below the minimum detectable level (MDL) were replaced with the MDL value for that sample. All values above the MDL were used as reported.

**Computational room air level model**

The well-mixed model is described in detail elsewhere and was previously validated with experimental data; it allows an estimation of aerosol dispersion and room air levels of individual constituents in an indoor space [18]. The model was developed to estimate room air levels of four constituents - nicotine, formaldehyde, acrolein and acetaldehyde, as these were the only ones that were quantifiable above the detection limits. Test Product 3 was selected for modeling estimates as it yielded relatively higher formaldehyde values in exhaled breath among the Test Products in the study. The model predicts vapor-particle partitioning and concentrations of chemical constituents of aerosol over time, as they travel...
through a defined indoor space. Input variables (Fig. 2) include space setting (space type and volume such as car, office space, or a restaurant), ventilation rate (fresh air exchange rate in air change per hour), exhaled aerosol (the amount of total aerosol exhaled by all users), and aerosol composition (mass fraction of each constituents of interest in the exhaled aerosol). The model is based on physical and thermodynamic interactions between air, vapor, and the particulate phase of the aerosol. These processes are mathematically represented by a set of simultaneous equations including conservation of mass, vapor/liquid partitioning, air flow and species transport, and mixing processes [18].

The EVP user exhaled breath results from the present study and historic sidestream smoke from a traditional cigarette were entered into a well-mixed computational model to estimate concentrations of aerosol constituents in three space settings where EVPs or combustible cigarettes are used: (1) car (3.17 m$^3$, closed versus open [3-inch gap] windows, 2 users among 4 occupants), (2) meeting room (81 m$^3$, 3 users among 15 occupants), and (3) restaurant (270 m$^3$, 15 users among 100 occupants). These concentrations were compared with corresponding values from the use of conventional cigarettes as well as with the permissible exposure limits (PELs) of the Occupational Safety and Health Administration [19]. The prevalence of smokers among the adult population in the United States was obtained from Centers for Disease Control report [20], and the same prevalence was assumed for EVP use. One cigarette per hour for 16 hours was used for daily cigarette consumption to allow for easy 1-hour exposure blocks and is similar to data on the daily consumption of cigarettes [20]. E-liquid consumption per day was based on approximately 902 mg average daily e-liquid consumption (average daily consumption during 7 days in-clinic assessment of exclusive use of Test Product 3 by smokers [16 hours ad libitum use per day]) [21]. Intake by non-users was based on the assumption that 100% of inhaled analytes are absorbed and estimated as follows: average concentration × exposure duration × breathing volume × breathing rate. A breathing volume of 500 mL at a rate of 12 breaths/minute was used in all calculations.

**Results**

**Participant characteristics and safety**

The mean age of study participants (n = 35) was 35 years (range 23–62 years). A total of 20 males (57.1%) and 15 females (42.9%) were enrolled into the product trial; 68.6% of subjects were African American, 28.6% were Caucasian, and 2.9% self-reported as belonging to a race other than African American or Caucasian.

Three subjects discontinued participation before randomization. One female subject who was unwilling/unable to use all four e-liquids (on Day One), and two additional male subjects were never randomized into the study because enrollment had been met. A total of 32 subjects were randomized and all subjects completed the study.

All four e-liquids were well-tolerated, with seven (20.0%) subjects experiencing a combined total of 12 adverse events (AEs) that were mild in severity. The most common AE was rash (three subjects
experienced one event each). Only 4 of the 12 AEs were considered related to the test EVP by the principal investigator. These four related AEs (coughing, oral discomfort, vomiting, and dizziness) were reported by only one subject each (2.9% of total subjects, respectively). No serious AEs were reported.

**Exhaled breath**

The ranges of measured levels of each of the detected analytes were calculated using exhaled breath samples and substantial variability was observed for each analyte (Fig. 1). Acetaldehyde and acrolein were all below the MDLs in all exhaled breath samples and therefore not analyzed further. Menthol and formaldehyde levels in exhaled breath samples of subjects were below the MDLs in 50% and 17%, respectively of exhaled breath samples (Supplementary Table S2). We note that large variability was observed in formaldehyde measurements for both Sham and Test Product use (Fig. 1). The average amount of e-liquid consumed during the collections ranged from 33.7 mg to 41.2 mg (Table 1). The amounts of each analyte present in exhaled breath samples were analyzed using linear mixed effects ANCOVA models. The data revealed that sham-corrected ANCOVA least square means (95% confidence interval [CI]) in 10 puffs for the four most abundant analytes were significantly different from zero (Table 2). Sham-corrected ANCOVA least square means (95% CI) for menthol showed significant differences from zero only after use of menthol-flavored e-liquids (Test Products 3 and 4). The amounts of any of the seven analytes in the exhaled breath of subjects were not significantly affected by study period or sequence of EVP use. Observed, sham-corrected amounts of nicotine (least square means ranged from 89.44 to 195.70 µg), propylene glycol (least square means ranged from 1,199.7 to 3,354.5 µg), glycerin (least square means ranged from 5,366.8 to 6,484.7 µg), and formaldehyde (least square means ranged from 0.25 to 0.34 µg) in 10 puffs were significantly different from zero ($p < 0.05$) in subjects’ exhaled breath after use of every e-liquid. Test Products 2 and 4 contained the highest percentage NBW (4.0%) and yielded the highest nicotine amounts in exhaled breath samples (195.70 and 182.65 µg, respectively). Differences in sham-corrected menthol amounts were only significantly different from zero after mentholated e-liquid use (Test Products 3 and 4; 21.11 and 31.01 µg, respectively).

Table 1

| Exhaled breath collection | Test Product 1 | Test Product 2 | Test Product 3 | Test Product 4 |
|---------------------------|----------------|----------------|----------------|----------------|
| n                         | 32             | 32             | 32             | 32             |
| **Collection 1**          |                |                |                |                |
| (Nicotine, propylene glycol, glycerin, menthol) | Mean (mg) 35.2 | 33.7 | 40.2 | 36.7 |
|                           | SD 8.70        | 11.37          | 12.6           | 12.32          |
| **Collection 2**          |                |                |                |                |
| (Formaldehyde, acetaldehyde, acrolein) | Mean (mg) 35.6 | 36.3 | 41.2 | 37.9 |
|                           | SD 11.53       | 11.94          | 14.58          | 12.4           |
Table 2
Summary of estimates from mixed effects analysis of covariance model for sham-corrected analytes.

| Analyte         | Test Product e-liquid | N  | Least square mean (95% CI) [µg] | p^A         |
|-----------------|-----------------------|----|---------------------------------|------------|
| Nicotine        | Test Product 1        | 32 | 89.44 (15.77, 163.11)           | 0.0184     |
|                 | Test Product 2        | 32 | 195.70 (122.01, 269.38)         | < 0.0001   |
|                 | Test Product 3        | 32 | 168.83 (95.17, 242.50)          | < 0.0001   |
|                 | Test Product 4        | 32 | 182.65 (108.63, 256.67)         | < 0.0001   |
| Propylene glycol| Test Product 1        | 32 | 1678.4 (592.14, 2764.6)         | 0.0031     |
|                 | Test Product 2        | 32 | 1199.7 (113.74, 2285.7)         | 0.0310     |
|                 | Test Product 3        | 32 | 3354.5 (2266.6, 4442.3)         | < 0.0001   |
|                 | Test Product 4        | 32 | 2511.0 (1416.1, 3605.9)         | < 0.0001   |
| Glycerin        | Test Product 1        | 32 | 5,972.3 (4,191.1, 7,753.6)      | < 0.0001   |
|                 | Test Product 2        | 32 | 6,099.5 (4,317.8, 7,881.2)      | < 0.0001   |
|                 | Test Product 3        | 32 | 6,484.7 (4,701.7, 8,267.6)      | < 0.0001   |
|                 | Test Product 4        | 32 | 5,366.8 (3,575.9, 7,157.7)      | < 0.0001   |
| Menthol         | Test Product 1        | 32 | 0.17 (–2.92, 3.25)              | 0.9150     |
|                 | Test Product 2        | 32 | 0.35 (–2.70, 3.40)              | 0.8217     |
|                 | Test Product 3        | 32 | 21.11 (18.06, 24.16)            | < 0.0001   |
|                 | Test Product 4        | 32 | 31.01 (27.91, 34.12)            | < 0.0001   |
| Formaldehyde    | Test Product 1        | 32 | 0.25 (0.12, 0.38)               | 0.0002     |
|                 | Test Product 2        | 32 | 0.25 (0.12, 0.38)               | 0.0003     |
|                 | Test Product 3        | 32 | 0.34 (0.21, 0.47)               | < 0.0001   |
|                 | Test Product 4        | 32 | 0.30 (0.17, 0.43)               | < 0.0001   |

ANCOVA = analysis of covariance; CI = confidence interval; NBW = nicotine by weight.

A Test whether the sham corrected value is different than 0

**Modeling room air levels and non-user intake**

The sham-corrected exhaled breath concentrations were used as inputs to a computational room air level model (Fig. 2). The input for the room air level modeling are outlined in Table 3 and the estimated room
air levels for four space settings are available in Supplementary Table S3 (a-g). The estimated intake by non-users in the space settings shared with cigarette smokers or EVP users are listed in Table 4.

| Constituent       | Traditional cigarette sidestream emission<sup>A</sup> (µg per cigarette) | Amount exhaled<sup>B</sup> per mg e-liquid consumed<sup>C</sup> (µg) |
|-------------------|--------------------------------------------------------------------------|---------------------------------------------------------------|
| Nicotine          | 5600                                                                     | 4.22                                                          |
| Propylene Glycol  | NA                                                                       | 83.86                                                         |
| Glycerin          | NA                                                                       | 162.12                                                        |
| Menthol           | NA                                                                       | 0.53                                                          |
| Formaldehyde      | 700                                                                      | 0.0083                                                        |
| Acetaldehyde      | 4200                                                                     | 0<sup>D</sup>                                                 |
| Acrolein          | 1300                                                                     | 0<sup>D</sup>                                                 |

<sup>A</sup> Sidestream values from a Kentucky reference 1R4F cigarette  
<sup>B</sup> Results from ANCOVA analysis;  
<sup>C</sup> 40 mg used for collection 1 and 41 mg used for collection 2 (rounded Test Product 3 data; Table 1)  
<sup>D</sup> Below detection limits in exhaled breath collections for both sham and after e-vapor use
Table 4
Estimated intake\(^\text{A}\) by non-users.

| Test space          | Duration (h) | Intake after cigarette use (µg)\(^\text{B}\) | Intake after EVP use (µg)\(^\text{C}\) | Intake based on 8-hour exposure to OSHA PELs (µg) |
|---------------------|--------------|---------------------------------------------|----------------------------------------|--------------------------------------------------|
| **Nicotine**        |              |                                             |                                        |                                                  |
| Car (closed windows)| 1            | 50.95                                       | 2.07                                   | 1440                                             |
| Car (open windows)  | 1            | 24.37                                       | 1.01                                   |                                                  |
| Meeting room        | 4            | 158.6                                       | 6.57                                   |                                                  |
| Restaurant          | 2            | 41.39                                       | 1.75                                   |                                                  |
| **Propylene glycol**|              |                                             |                                        |                                                  |
| Car (closed windows)| 1            | N/A                                         | 41.31                                  | 28,800                                           |
| Car (open windows)  | 1            | N/A                                         | 20.19                                  |                                                  |
| Meeting room        | 4            | N/A                                         | 130.56                                 |                                                  |
| Restaurant          | 2            | N/A                                         | 34.95                                  |                                                  |
| **Glycerin**        |              |                                             |                                        |                                                  |
| Car (closed windows)| 1            | N/A                                         | 79.85                                  | 28,800                                           |
| Car (open windows)  | 1            | N/A                                         | 39.04                                  |                                                  |
| Meeting room        | 4            | N/A                                         | 252.40                                 |                                                  |
| Restaurant          | 2            | N/A                                         | 67.57                                  |                                                  |
| **Formaldehyde**    |              |                                             |                                        |                                                  |
| Car (closed windows)| 1            | 6.36                                        | 0.00408                                | 2650                                             |

\(^\text{A}\) Intake = (average concentration) × (exposure duration) × (breathing volume) × (breathing rate)

\(^\text{B}\) N/A refers to the cases where no data are available for that constituent in sidestream smoke for comparison.

\(^\text{C}\) Zero values represent cases where the measure concentration of a constituent is below the level of quantification.
| Test space       | Duration (h) | Intake after cigarette use (µg)\(^B\) | Intake after EVP use (µg)\(^C\) | Intake based on 8-hour exposure to OSHA PELs (µg) |
|------------------|--------------|----------------------------------------|---------------------------------|-----------------------------------------------|
| Car (open windows) | 1            | 3.04                                   | 0.000199                        |                                               |
| Meeting room     | 4            | 19.83                                  | 0.01291                         |                                               |
| Restaurant       | 2            | 5.17                                   | 0.00345                         |                                               |
| **Acetaldehyde** |              |                                        |                                 |                                               |
| Car (closed windows) | 1            | 12.28                                  | 0                               | 1,036,800                                     |
| Car (open windows) | 1            | 5.88                                   | 0                               |                                               |
| Meeting room     | 4            | 38.25                                  | 0                               |                                               |
| Restaurant       | 2            | 9.98                                   | 0                               |                                               |
| **Acrolein**     |              |                                        |                                 |                                               |
| Car (closed windows) | 1            | 38.2                                   | 0                               | 720                                           |
| Car (open windows) | 1            | 18.29                                  | 0                               |                                               |
| Meeting room     | 4            | 119.00                                 | 0                               |                                               |
| Restaurant       | 2            | 31.05                                  | 0                               |                                               |

\(^A\) Intake = \(\text{(average concentration)} \times \text{(exposure duration)} \times \text{(breathing volume)} \times \text{(breathing rate)}\)

\(^B\) N/A refers to the cases where no data are available for that constituent in sidestream smoke for comparison.

\(^C\) Zero values represent cases where the measure concentration of a constituent is below the level of quantification.

The results indicate that non-user intake of nicotine, formaldehyde, acrolein, and acetaldehyde would occur, but at substantially lower levels during EVP use compared with secondhand exposure to conventional cigarettes (Table 4). No data for PG or glycerin in sidestream smoke were available to compare with the EVP case. However, room-level measurements of constituents show that the average concentrations of PG in a room where cigarettes and EVPs were used \textit{ad libitum} were 66 and 132 µg/m\(^3\), respectively [5]. The respective values for glycerin in that study were below the level of quantification and 78 µg/m\(^3\) for cigarettes and EVPs, respectively [5].
For reference, the modeled indoor air levels were compared to the Occupational Health and Safety Administration (OSHA) PELs, defined as the limit of the total average airborne exposure in any 8-hour work shift of a 40-hour work week. The OSHA PELs are as follows: nicotine, 500 µg/m³; glycerin, 10,000 µg/m³; formaldehyde 920 µg/m³; acetaldehyde, 360,000 µg/m³; and acrolein, 250 µg/m³ [19]. Computational modeling showed that analyte concentrations in air after EVP use for all modeled indoor spaces (Table 4, Supplemental Table S3a-g) were orders of magnitude less than the OSHA PELs for an 8-hour workday.

Discussion

The key findings from the exhaled breath assessment were: (1) samples from all subjects were below detectable levels for acetaldehyde and acrolein after EVP use; (2) menthol was detected only in the two mentholated e-liquids; (3) nicotine, glycerin, propylene glycol, and formaldehyde were detected in the exhaled breath of subjects for all four e-liquids; and, (4) significant variability existed between subjects in the amount of analytes in exhaled breath, despite subjects using prespecified puffing conditions. These data from real users were entered into a well-mixed model to estimate potential secondhand exposure. The key findings from the computational model were: (1) the computational model is fit-for-purpose to predict constituent levels under various real-world scenarios; (2) room air levels of nicotine, formaldehyde, acrolein, and acetaldehyde levels were significantly below OSHA PELs or American Industrial Hygiene Association (AIHA) limit; and (3) intake of these constituents by non-users would be substantially lower in the presence of EVP use compared with secondhand exposure to conventional combustible cigarettes.

These findings are consistent with previous machine puffing and exhaled breath studies that showed wide variabilities in analyte amounts across different EVPs [13, 14]. Exhaled breath or aerosols from such studies consistently showed that nicotine, propylene glycol, and glycerin were present in higher concentrations than the other analytes characterized in the current study due to the fact that propylene glycol and glycerin are the main nicotine carriers in e-liquids. Similar to our findings, another group reported that formaldehyde levels were low and that acetaldehyde and acrolein were undetectable in various brands of EVPs [14]. However, others measured detectable levels of these compounds depending on the device and e-liquid used [9, 22].

The main finding from the well-mixed modeling was the establishment of a fit-for-purpose computational model to predict room air levels under various real-world scenarios. The test space concentrations of nicotine, formaldehyde, acetaldehyde, and acrolein were significantly less with EVPs compared to cigarettes under equivalent use conditions. Propylene glycol and glycerin levels in air from EVP use were orders of magnitude less than OSHA PELs and the AIHA limit for all studied spaces.

The well-mixed model findings were used to estimate exposure to non-users. The predicted nicotine exposure was roughly 20-fold lower for EVP use versus cigarettes for all space settings. The difference in estimated formaldehyde exposure was even more dramatic; predicted intake by non-users ranged from 3.04 to 19.83 µg for cigarettes compared to 0.002 to 0.013 µg for EVPs (~ 1500-fold difference). The
formaldehyde range is comparable to that reported by Visser and colleagues, who modeled non-user exposure in two scenarios [12]. Our nicotine range was higher, possibly because the EVPs in their study had lower NBW values and/or their modeling was based on 5 puffs instead of 10. The 17 subjects in that study were also free to vape naturally in terms of preferred puff length, volume, and interval. Overall, our results are in concordance with previous reports that demonstrate while EVPs use may expose non-users to some secondhand constituents, they do not substantially increase non-user exposure to combustion toxicants [12, 23, 24].

Data from this study allowed for comparison of various analyte amounts in the four e-liquids and estimation of ambient analyte concentrations under various EVP use scenarios. User behavior, EVP characteristics, and the dimensions and ventilation of a space all influence air concentrations. The highest predicted non-user intake was for our meeting room scenario where three people were using EVPs during a 4-hour period. This is an extreme example, but expected intakes were still dramatically lower than OSHA PELs. The lowest values were in a car with open windows, which is not surprising, likely due to cross ventilation through the open windows. While conventional cigarette smokers open the windows out of necessity, EVP users may not do so. Our modeling suggests that non-user exposure could be halved if the car windows are 3 inches open during EVP use. Importantly, predicted non-user intake of formaldehyde and nicotine were several-fold lower than for conventional cigarettes.

Only a few studies have investigated secondhand exposure to EVP analytes using exhaled breath samples, and to our knowledge, the current study included the largest number of users. There were, however, several limitations to this study (1) The subjects were instructed to take 5-second puffs with a fresh cartridge, and this might not be their usual puff duration or reflect the entire use of a cartridge. (2) The study only tested a limited number of analytes in four different flavors of the same cartridge-based EVP and therefore did not comprehensively characterize the values of the various analytes in the wide, fast-growing array of EVPs. (3) The degree of passive exposure depends on multiple factors such as specific product and how it is used, ventilation rate, space size, humidity, and number of users, some of which were included in our model. Despite these limitations, our results show the utility of this modeling approach for studying non-user exposure.

**Conclusions**

Use of any of the four e-liquids resulted in significant increases versus sham in the amounts of four of seven analytes in exhaled breath: nicotine, glycerin, propylene glycol, and formaldehyde. In addition, use of both mentholated e-liquids (Test Products 3 and 4) resulted in significant increases from sham in the amount of menthol in exhaled breath. Acetaldehyde and acrolein were not detectable after any of the Test EVP use. When these data were used as inputs to a computational room air level and non-user intake model, the ambient concentrations of exhaled nicotine and formaldehyde predicted that non-user intakes were substantially reduced for Test EVP use compared to conventional cigarette use. Collectively, the results predict that room air levels of the selected analytes were relatively low and several-fold below regulatory PELs and AIHA limit under the modeled space and use conditions. The computational model
may be useful in assessing room air levels of constituents among different types of EVPs and estimate potential secondhand EVP exposure under various real-world settings.

**List Of Abbreviations**

AE = Adverse Event  
AIHA = American Industrial Hygiene Association  
ANCOVA = Analysis of Covariance  
CFR = Code of Federal Regulation  
GCP = Good Clinical Practice  
IRB = Institutional Review Board  
MDL = Minimum Detectable Level  
NBW = Nicotine by weight (%)  
OSHA = Occupation Safety and Health Administration  
PEL = Permissible Exposure Limit  
PG = Propylene Glycol  
TP = Test Product  
µg = micro gram

**Declarations**

**Ethics approval and consent to participate**

The protocol and informed consent form for the exhaled breath collection was approved by the Chesapeake IRB (Columbia, MD – Note now Advarra IRB). OHRP/FDA IRB Registration Number: IRB#00000790. Protocol approval: Pro00020903 (initial). The subsequent modifications each have a unique number (MOD00201162, MOD00202577).

**Consent for publication**

Not applicable. The manuscript does not contain any individual’s personal data, hence

**Availability of data and material**
The datasets during and/or analysed during the current study available from the corresponding author on reasonable request.

**Competing interests**

All authors are employed by Altria Client Services LLC during the conduct of this work. We note that the Test Products are no longer sold commercially, and Altria does not sell any e-vapor products. Therefore, the authors declare that they have no competing interests.

**Funding**

The study was funded by Altria Client Services LLC, and conducted on behalf of NuMark LLC, Richmond, VA.

**Authors’ contributions**

JSE and MAS conceptualized the study design. JSE managed the conduct of the study. QL was responsible for developing the statistical analysis plan and supervising the data management and statistical analyses. SM managed the bioanalysis. AR developed and conducted the computational modeling. MS supervised the overall project. JSE, QL and MAS were responsible for writing the manuscript.

**Acknowledgements**

The authors would like to thank Lindsay Reese for her manuscript drafting and editing assistance and Alisia Daily for manuscript project management.

**References**

1. Azzopardi D, Patel K, Jaunky T, et al. Electronic cigarette aerosol induces significantly less cytotoxicity than tobacco smoke. Toxicol Mech Methods. 2016(6);26:477–91.

2. Hess, CA, Olmedo P, Navas-Acien A, Goessler W, Cohen JE, Rule AM.. E-cigarettes as a source of toxic and potentially carcinogenic metals. Environ Res. 2017;152:221–5.

3. Royal College of Physicians of London. Nicotine without smoke: Tobacco harm reduction. 2016. Available at [https://www.rcplondon.ac.uk/projects/outputs/nicotine-without-smoke-tobacco-harm-reduction-0](https://www.rcplondon.ac.uk/projects/outputs/nicotine-without-smoke-tobacco-harm-reduction-0). Accessed November 5, 2018.

4. Flora JW, Meruva N, Huang CB, et al. Characterization of potential impurities and degradation products in electronic cigarette formulations and aerosols. Regul Toxicol Pharmacol. 2016;74:1–11.

5. Liu J, Liang Q, Oldham MJ, et al. Determination of Selected Chemical Levels in Room Air and on Surfaces after the Use of Cartridge- and Tank-Based E-Vapor Products or Conventional Cigarettes. Int J Environ Res Public Health. 2017;14(9):E969.
6. Wagner KA, Flora JW, Melvin MS, et al. An evaluation of electronic cigarette formulations and aerosols for harmful and potentially harmful constituents (HPHCs) typically derived from combustion. Regul Toxicol Pharmacol. 2018;95:153–60.

7. Rodgman A, Smith CJ, Perfetti TA. The composition of cigarette smoke: a retrospective, with emphasis on polycyclic components. Hum Exp Toxicol. 2000;19(10):573–95.

8. Sarkar M, Kapur S, Frost-Pineda K, Feng S, Wang J, Liang Q, Roethig H. Evaluation of biomarkers of exposure to selected cigarette smoke constituents in adult smokers switched to carbon-filtered cigarettes in short-term and long-term clinical studies. Nicotine Tob Res. 2008;10(12):1761–72.

9. Long GA. Comparison of select analytes in exhaled aerosol from e-cigarettes with exhaled smoke from a conventional cigarette and exhaled breaths. Int J Environ Res Public Health. 2014;11(11):11177–91.

10. Stephens WE. Comparing the cancer potencies of emissions from vapourised nicotine products including e-cigarettes with those of tobacco smoke. Tob Control. 2018;27:10–7.

11. Hutzler C, Paschke M, Kruschinski S, Henkler F, Hahn J, Luch A. Chemical hazards present in liquids and vapors of electronic cigarettes. Arch Toxicol. 2014;88(7):1295–308.

12. Visser WF, Klerx WN, Cremers HWJM, Ramlal R, Schwillens PL, Talhout R. The health risk of electronic cigarette use to bystanders. Int J Environ Res Public Health. 2019;16(9):E1525.

13. Cheng T. Chemical evaluation of electronic cigarettes. Tob Control. 2014;23 Suppl 2: ii11–ii17.

14. Goniewicz ML, Knysak J, Gawron M, et al. Levels of selected carcinogens and toxicants in vapour from electronic cigarettes. Tob Control. 2014;23(2):133–9.

15. Herrington JS, Myers C. Electronic cigarette solutions and resultant aerosol profiles. J Chromatogr A. 2015;1418:192–9.

16. Hess IM, Lachireddy K, Capon A. A systematic review of the health risks from passive exposure to electronic cigarette vapour. Public Health Res Pract. 2016;26(2):2621617.

17. Oldham MJ, Wagner KA, Gene Gilman I, et al. Development/verification of methods for measurement of exhaled breath and environmental e-vapor product aerosol. Regul Toxicol Pharmacol. 2017;85:55–63.

18. Rostami AA, Pithawalla YB, Liu J, et al. A Well-Mixed Computational Model for Estimating Room Air Levels of Selected Constituents from E-Vapor Product Use. Int J Environ Res Public Health. 2016;13(8):E828.

19. Occupational Safety and Health Administration (OSHA). Permissible exposure limits – annotated tables. Available at https://www.osha.gov/dsg/annotated-pels/. Accessed on September 1, 2019.

20. Jamal A, King BA, Neff LJ, Whitmill J, Babb SD, Graffunder CM. Current Cigarette Smoking Among Adults - United States, 2005-2015. MMWR Morb Mortal Wkly Rep. 2016;65(44):1205–11.

21. Edmiston J, Oliveri D, Wang J, Sarkar M. Characterization of Exposure to Cigarette Smoke Constituents in Adult Smokers Switching to E-Vapor Products. Poster presented at: American College of Clinical Pharmacology Annual Meeting; 2019 Sep 15-17; Chicago, IL.
22. Samburova V, Bhattarai C, Strickland M, et al. Aldehydes in exhaled breath during E-cigarette vaping: Pilot study results. Toxics. 2018;6(3):E46.

23. Czogala J, Goniewicz ML, Fidelus B, Zielinska-Danch W, Travers MJ, Sobczak A. Secondhand exposure to vapors from electronic cigarettes. Nicotine Tob Res. 2014;16(6):655–62.

24. Johnson JM, Naeher LP, Yu X, et al. A biomonitoring assessment of secondhand exposures to electronic cigarette emissions. Int J Hyg Environ Health. 2019;222(5):816–23.

Figures
Distributions of sham and EVP exhaled breath measurements of nicotine, propylene glycol, glycerin, formaldehyde, and menthol during 10 puffs at 5 seconds each. A, nicotine; B, glycerin; C, propylene glycol; D, menthol; E, formaldehyde. TP = Test Product. Levels below the minimum detection limit were set to the minimum detection limit. Outliers are represented by open circles and plus signs for EVP and sham, respectively; means are represented by the closed circles; first quartiles are represented by the bottom of
the boxes; medians are represented by the top of the boxes; and 1.5 times the first and third quartiles are represented by the lines extending below and above the boxes, respectively. Blue and red bars indicate sham and EVP values, respectively.

Figure 2

Schematic of the non-user exposure characterization models. The physics-based model considers fluid flow, mass and heat transfers, and thermodynamic and kinetic interactions.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementalTablesBMCPublicHealth.docx